NYSE
26.11USD
-0.46 (-1.73%)
We have scored 45 news catalysts on Doximity, Inc. (DOCS) over the past 12 months. The biggest single-day move next to one of them came Aug 8, 2026, when DOCS closed +32.6%: “Doximity: I Called The Pop Over A Month Ago, But Now Is The Time To Wait (Rating Downgrade)”. Coverage across the window leans negative (average ticker sentiment −0.10). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4.9B
P/E
—
EPS
—
Beta
1.25
52W range
17.15-76.51
Day range
25.95–26.51
Open
26.50
Prev close
26.57
Volume
7.1M
Avg volume
4.8M
Dividend
0.00
IPO
2021-06-24
Analysts publish price targets on DOCS, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
18 analyst price targets from $18 to $41
as of 2026-09-05
The market is within 3% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Doximity, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for DOCS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Doximity, Inc. provides a digital platform, hosted in the cloud, specifically designed for healthcare practitioners throughout the United States. This platform delivers a suite of specialized tools, empowering its members to connect with peers, streamline patient treatment, conduct remote consultations, access current medical information and research, and advance their professional careers. Its primary clientele consists of pharmaceutical companies and healthcare organizations. Established in 2010, the entity initially operated as 3MD Communications, Inc. before rebranding to Doximity, Inc. in June of that year. The company's corporate headquarters are situated in San Francisco, California.
The price sits at the 56th percentile of published models, broadly endorsing the middle view that growth decelerates to near-zero, while explicitly rejecting both the bull case for AI monetization and the bear case for core disruption.
What the disagreement turns on
Does Doximity's new AI Search and Scribe actually convert physician intent into new, high-margin pharmaceutical budgets, or does it merely cannibalize the existing core while adding compute costs — and the only wired observable (unit volumes via segment revenue) can confirm the top-line acceleration but cannot measure the intent or margin conversion directly.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
